多西他赛一线治疗老年晚期非小细胞肺癌临床分析  

Observation of domestic docetaxel in the first line treatment of elderly patients with advanced non-small cell lung cancer

作　　者：牟玲[1] 孟令新[1] 尹强[1] 李玉锋[1] 刘山[1] 李明焕[2] 

机构地区：[1]山东省日照市人民医院肿瘤科,276826 [2]山东省肿瘤医院放疗一科

出　　处：《中国医药》2010年第2期100-102,共3页China Medicine

基　　金：基金项目：国家自然科学基金青年科学基金项目（30801051）,国家自然科学基金面上项目（30872997）

摘　　要：目的观察多西他赛单药一线治疗老年晚期非小细胞肺癌的临床疗效。方法72例老年晚期非小细胞肺癌初治患者以国产多西他赛（商品名：奥名润）50～60mg／m2，溶于生理盐水250ml中，第1、8天给药，21d为一周期，每完成2周期化疗后评价疗效，有效及稳定病例完成4周期，随访疾病进展至患者死亡。结果72例可评价病例中，总有效率为26．4％，疾病控制率为52．8％，中位无进展生存期3．2个月，中位生存期8．4个月，1年、2年生存率分别为33．9％、18．6％。全组患者的性别、ECOG评分和临床分期3项指标在治疗后的中位生存期方面差异有统计学意义（P〈0．05）。不良反应以粒细胞减少、乏力和脱发为主，分别为52．78％、36．11％和43．06％。结论国产多西他赛单药治疗老年晚期非小细胞肺癌显示了较好的疗效，患者安全性及耐受性较好，值得临床推广使用。Objective To observe the efficacy of domestic docetaxel in the first line treatment of 72 cases elderly patients with advanced non-small cell lung cancer （NSCLC）. Methods Totally 72 elderly patients with NSCLC were treated with domestic docetaxel with a dose of 50 ～ 60 mg/m2 on day 1 and day 8. Re-evaluation was done after every two cycles. Those who did not have tumor progression went through other two cycles of chemotherapy and all patients were followed up until disease progressed or patients died. Results Seventy-two patients were evaluated and shoured 26.4% response rate, 52.8% stable disease,3.2 months of median progression free survival （PFS） , 8.4 months of median OS and 33.9% , 18.6% 1-year,2-year survival rate, respectively, Female patients had better outcomes than the male. Patients with good performance status（PS） had better results than those without good PS. Patients with stage Ⅲ B had better results than stage Ⅳ and those with less co-morbidities had better resuits than those with more internal illness in subgroup analysis. There was statistical significance among different gender, performance status and clinical stage in terms of overall survival （ P 〈 0.05 ）. The common adverse events were neutropenia（52.78% ）, asthenia（36.11% ） and alopecia（43.06% ）. Conclusion Domestic docetaxel is an effective first line treatment for elderly patients with advanced NSCLC.

关 键 词：肺肿瘤 老年非小细胞肺癌 多西他赛 一线治疗 

分 类 号：R734.2[医药卫生—肿瘤]